ASH 2022 | EPCORE NHL-2: epcoritamab with rituximab and lenalidomide in newly diagnosed and R/R FL
Lorenzo Falchi, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the rationale and results from two arms of the EPCORE NHL-2 Phase I/II trial (NCT04663347) evaluating the safety and efficacy of subcutaneous epcoritamab in combination with rituximab and lenalidomide in patients with newly diagnosed and relapsed/refractory (R/R) follicular lymphoma (FL). Both trial arms reported promising results in terms of both efficacy and safety, with low-grade, manageable adverse events (AEs). Dr Falchi then discusses where this combination therapy may fit in the treatment regimen of FL, arguing that whilst in the R/R setting, this combination is likely to become a new standard of care (SOC), more data is needed to assess the benefit of this therapy in the frontline setting. This interview took place at the 64th ASH Annual Meeting and Exposition Congress held in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Genmab: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; Genentech/Roche: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; ADC Therapeutics: Membership on an entity’s Board of Directors or advisory committees; Astrazeneca: Membership on an entity’s Board of Directors or advisory committees; Seagen: Membership on an entity’s Board of Directors or advisory committees.
